Efficacy and Safety of Polymer-Free Ultrathin Strut Sirolimus-Probucol Coated Drug-Eluting Stents for Chronic Total Occlusions: Insights from the Coroflex ISAR 2000 Worldwide Registry

Table 1

Patient demographics.

Variable		Patients, n (%)	<25 mm lesion length, n (%)	≥25 mm lesion length, n (%)	value
Number of patients		111 (100%)	49 (44.1%)	62 (55.8%)	—
Number of lesions		127 (100%)	58 (45.7%)	69 (54.3%)	—
Number of DES used		160 (100%)	65 (40.6%)	95 (59.4%)	—
Age (years)		64.9 ± 11.6	64.8 ± 12.3	65.0 ± 11.0	0.942
Male gender		82 (73.9%)	35 (71.4%)	47 (75.8%)	0.602
Diabetes		50 (45.0%)	19 (38.8%)	31 (50.0%)	0.238
Hypertension		79 (71.2%)	30 (61.2%)	49 (79.0%)	0.040
Renal insufficiency		6 (5.4%)	3 (6.1%)	3 (4.8%)	0.766
Dialysis dependence		1 (0.9%)	0 (0.0%)	1 (1.6%)	0.372
STEMI		9 (8.1%)	2 (4.1%)	7 (11.3%)	0.257
NSTEMI		14 (12.6%)	8 (16.3%)	6 (9.7%)
Region	Europe	71 (64.0%)	29 (59.2%)	42 (67.7%)	0.351
	Asia	40 (36.0%)	20 (40.8%)	20 (32.3%)